Ozmosi | Midecamycin Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Midecamycin

Alternative Names: midecamycin
Clinical Status: Inactive
Latest Update: 2023-05-22
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action:

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: Bosnia | Bulgaria | Chile | Dominican Republic | Egypt | Hong Kong | Italy | Korea | Malta | Pakistan | Peru | Portugal | Russia | Saudi Arabia | Serbia | Slovenia | Taiwan | Ukraine | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

Recent News Events

Date

Type

Title

05/22/2023

PubMed

 Novel mechanisms of macrolide resistance revealed by in vitro selection and genome analysis in Mycoplasma pneumoniae.

12/01/2022

PubMed

 Pathogenicity of Plesiomonas shigelloides and Citrobacter freundii isolated from the endangered Chinese sturgeon (Acipenser sinensis).

08/05/2022

PubMed

 Controlling the Site Selectivity in Acylations of Amphiphilic Diols: Directing the Reaction toward the Apolar Domain in a Model Diol and the Midecamycin A(1) Macrolide Antibiotic.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions